Business
Director/PDMR Shareholding
Director/PDMR Shareholding.
About this update from Bsf Enterprise Plc
[{"type":"text","content":"\n\n \n18 June 2024\nBSF Enterprise PLC\n(\"BSF\" or the \"Company\")\n \nNOTIFICATION OF TRANSACTIONS OF DIRECTORS\n \nBSF (LSE: BSFA), (OTCQB: BSFAF), has received notification from its CFO, Graham Duncan, being a person discharging managerial responsibilities, of the purchase of shares as set out in the notification of dealing form here:\nhttp://bsfenterprise.com/wp-content/uploads/2024/06/PDMR_Notification_00380329.pdf\n \n \n \nFor further enquiries, please visit www.bsfenterprise.com or contact:\n\n\n\n\n \n \nBSF Enterprise PLC\n\n\n \n \nVia SEC Newgate below\n\n\n\n\nGeoff Baker - Executive Director\nChe Connon - CEO & Director\n\n\n \n\n\n\n\n \nShard Capital (Broker)\n\n\n\n\n\n\n\nDamon Heath\nIsabella Pierre\n\n\n0207 186 9000\n0207 186 9927\n\n\n\n\n \nSEC Newgate (Financial Communications)\n\n\n\n\n\n\n\nBob Huxford\nElisabeth Cowell\nGeorge Esmond\n\n\n020 3757 6882\[email protected]\n\n\n\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nISIN of the Ordinary Shares is GB00BHNBDQ51\nSEDOL Code is BHNBDQ5.\n \n \nNotes to Editors\n \nBSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions to deliver sustainable materials and products across a variety of sectors. BSF Enterprise's core technology platform in industrial tissue engineering allows the manufacture at scale of lab-grown alternatives to animal and human tissues, helping deliver sustainable products and materials of the future. The Company's technologies have multiple applications across consumer and medical markets including lab-grown leather, cultivated meat, human corneas and in vitro animal models.\n \nBSF owns 100% of pioneering UK-based tissue engineering companies 3D Bio-Tissues (3DBT), that successfully produced the UK's first high-quality cultivated meat and lab-grown skin from its laboratory and Kerato, a developer of lab-grown corneal replacement tissue for medical and research uses. In addition, it owns 100% of BSF Enterprise (Hong Kong) Limited which is actively supporting commercialisation of our technology in China and Asia.\n \nBSF aims to deliver growth to shareholders through...